Increase in circulating holotranscobalamin after oral administration of cyanocobalamin or hydroxocobalamin in healthy adults with low and normal cobalamin status

European Journal of Nutrition, Oct 2017

Purpose To investigate the absorption of synthetic cyanocobalamin and natural occurring hydroxocobalamin in populations with low and normal cobalamin (vitamin B12) status. Methods We included adults with low (n = 59) and normal (n = 42) cobalamin status and measured the change in serum holotranscobalamin (ΔholoTC) before and after 2 day administration of different doses of cyanocobalamin and hydroxocobalamin (CobaSorb test). In the low status group, the test was performed using a cross-over design with identical doses of both cobalamin forms (1.5, 3, and 6 µg, respectively). In the normal status group, the test was performed with either 3, 6, and 9 µg cyanocobalamin (n = 28), or with 9 µg cyanocobalamin and 9 µg hydroxocobalamin (n = 14). Results In both groups, median ΔholoTC (pmol/L) was higher after intake of cyanocobalamin compared to (hydroxocobalamin) [low status: 1.5 µg: 19 (6); 3 µg: 23 (7); 6 µg: 30 (14); normal status: 9 µg: 30 (13) pmol/L]. Independent of B12 form, no difference was observed in ΔholoTC between those receiving 1.5 and 3 µg in the low status group or 6 and 9 µg cyanocobalamin in the normal status group. However, in both groups, administration of 6 µg cobalamin resulted in a significant higher ΔholoTC than did 3 µg [low status: p = 0.02 (0.009) for cyanocobalamin (hydroxocobalamin); normal status: p = 0.03 for cyanocobalamin]. Conclusions Administration of cyanocobalamin resulted in a more than twofold increase in holoTC in comparison with hydroxocobalamin. The absorptive capacity was reached only by doses above 3 µg cobalamin. Our results underscore the importance of using the same form of cobalamin when comparing uptake under different conditions. Clinical trial registry number NCT02832726 at https://​clinicaltrials.​gov and 2016/09/012147 at Clinical Trials Registry India.

A PDF file should load here. If you do not see its contents the file may be temporarily unavailable at the journal website or you do not have a PDF plug-in installed and enabled in your browser.

Alternatively, you can download the file locally and open with any standalone PDF reader:

https://link.springer.com/content/pdf/10.1007%2Fs00394-017-1553-5.pdf

Increase in circulating holotranscobalamin after oral administration of cyanocobalamin or hydroxocobalamin in healthy adults with low and normal cobalamin status

Increase in circulating holotranscobalamin after oral administration of cyanocobalamin or hydroxocobalamin in healthy adults with low and normal cobalamin status Eva Greibe 0 1 2 4 Namita Mahalle 0 1 2 4 Vijayshri Bhide 0 1 2 4 Christian W. Heegaard 0 1 2 4 Sadanand Naik 0 1 2 4 Ebba Nexo 0 1 2 4 0 Department of Molecular Biology and Genetics, Aarhus University , Aarhus , Denmark 1 Department of Pathology, Deenanath Mangeshkar Hospital and Research Center , Pune , India 2 Department of Clinical Biochemistry and Institute of Clinical Medicine, Aarhus University Hospital , Aarhus , Denmark 3 Sadanand Naik 4 Clinical Biochemistry, Deenanath Mangeshkar Hospital and Research Center , Pune , India Purpose To investigate the absorption of synthetic cyanocobalamin and natural occurring hydroxocobalamin in populations with low and normal cobalamin (vitamin B12) status. Methods We included adults with low (n = 59) and normal (n = 42) cobalamin status and measured the change in serum holotranscobalamin (ΔholoTC) before and after 2 day administration of different doses of cyanocobalamin and hydroxocobalamin (CobaSorb test). In the low status group, the test was performed using a cross-over design with identical doses of both cobalamin forms (1.5, 3, and 6 µg, respectively). In the normal status group, the test was performed with either 3, 6, and 9 µg cyanocobalamin (n = 28), or with 9 µg cyanocobalamin and 9 µg hydroxocobalamin (n = 14). Results In both groups, median ΔholoTC (pmol/L) was higher after intake of cyanocobalamin compared to (hydroxocobalamin) [low status: 1.5 µg: 19 (6); 3 µg: 23 (7); 6 µg: 30 (14); normal status: 9 µg: 30 (13) pmol/L]. Independent of B12 form, no difference was observed in ΔholoTC between those receiving 1.5 and 3 µg in the low status group or 6 and 9 µg cyanocobalamin in the normal status group. However, in both groups, administration of 6 µg cobalamin resulted in a significant higher ΔholoTC than did 3 µg [low status: p = 0.02 (0.009) for cyanocobalamin (hydroxocobalamin); normal status: p = 0.03 for cyanocobalamin]. Conclusions Administration of cyanocobalamin resulted in a more than twofold increase in holoTC in comparison with hydroxocobalamin. The absorptive capacity was reached only by doses above 3 µg cobalamin. Our results underscore the importance of using the same form of cobalamin when comparing uptake under different conditions. Clinical trial registry number NCT02832726 at https:// clinicaltrials.gov and 2016/09/012147 at Clinical Trials Registry India. Vitamin B12; Cyanocobalamin; Hydroxocobalamin; Holotranscobalamin; CobaSorb test; Cobalamin absorption Introduction Cobalamin (vitamin B12) is an essential micronutrient. Inadequate intake or impaired intestinal absorption leads to cobalamin deficiency and clinical signs of neurological impairment and/or anemia [ 1 ]. Cyanocobalamin (CN-Cbl) is the synthetic form of the vitamin, most often used in vitamin pills. In food items, cobalamin is present as hydroxocobalamin (HO-Cbl), or the coenzymes methylcobalamin or 5′-deoxyadenosylcobalamin [ 2 ]. Upon light exposure, the coenzymes are converted to HO-Cbl. A number of studies have investigated the absorption of CN-Cbl, while only a few over 40-year-old studies have compared the uptake of various other forms of the vitamin. Employing radioactive-labeled cobalamin and whole-body monitoring, Weisberg and Glass [ 3 ] found that CN-Cbl and HO-Cbl were equally absorbed at large pharmacological dosages (100–1000 µg), and Heinrich and Gabbe [ 4 ] and Adams et al. [ 5 ] confirmed these findings for low doses of cobalamin (< 5 µg). In more recent time, usage of radioactive-labeled cobalamin has not been considered suitable for human studies. To circumvent this problem, we designed a test that we named CobaSorb [ 6–8 ]. In its original design, serum holotranscobalamin (holoTC, active cobalamin) was measured before and after oral intake of three doses of 9 µg CN-Cbl for 2 days [ 6–8 ]. Further studies have shown that the test is suitable for judging cobalamin absorption even in a population with a low cobalamin status and that doses as low as 2 µg can be used [ 9 ]. The studies performed so far leave three questions unanswered. Does intake of cobalamin present in a vitamin pill (CN-Cbl) and present in food (HO-Cbl) result in similar increase in plasma holoTC? Which physiological dose of cobalamin should be administered to give the highest increase in holoTC? Moreover, is there any difference in the cobalamin-induced increase in holoTC between individuals with a low and a normal cobalamin status? In the present study, we address these questions. Subjects and methods Participants with low cobalamin status (group A) Participants were recruited from Pune, India, and the study was carried out at Deenanath Mangeshkar Hospital and Research Center, Pune, India, in the fall of 2015. In total, 62 healthy lacto-vegetarian Indian individuals aged ≥ 18 years were included. Mo (...truncated)


This is a preview of a remote PDF: https://link.springer.com/content/pdf/10.1007%2Fs00394-017-1553-5.pdf

Eva Greibe, Namita Mahalle, Vijayshri Bhide, Christian W. Heegaard, Sadanand Naik, Ebba Nexo. Increase in circulating holotranscobalamin after oral administration of cyanocobalamin or hydroxocobalamin in healthy adults with low and normal cobalamin status, European Journal of Nutrition, 2017, pp. 1-9, DOI: 10.1007/s00394-017-1553-5